What is claimed is:

1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71, wherein the first twenty amino acid residues of the sequence does not comprise a cysteine, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

2. The isolated polypeptide according to claim 1, wherein the polypeptide comprises at least 6 contiguous amino acids from the amino acid sequence at position 185-254 of SEQ ID NO: 71.

3. The isolated polypeptide according to claim 1, wherein the polypeptide is immunogenic.

4. The isolated polypeptide according to claim 1, wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 71.

5. An immunogenic composition comprising the polypeptide as in any of claims 1-4.

6. The immunogenic composition according to claim 5, further comprising an A12 polypeptide having the amino acid sequence SEQ ID NO: 66.

7. The immunogenic composition according to claim 5, further comprising an A05 polypeptide having the amino acid sequence SEQ ID NO: 76.

8. The immunogenic composition according to claim 5, further comprising an B09 polypeptide having the amino acid sequence SEQ ID NO: 49.

9. The immunogenic composition according to claim 5, further comprising an B44 polypeptide having the amino acid sequence SEQ ID NO: 44.

10. The immunogenic composition according to claim 5, further comprising an A12 polypeptide having the amino acid sequence SEQ ID NO: 66, a B09 polypeptide having the amino acid sequence SEQ ID NO: 49, and a B44 polypeptide having the aa sequence SEQ ID NO: 44.

11. The immunogenic composition according to claim 5, further comprising an A05, A12, B09, and B44 polypeptide having the amino acid sequence SEQ ID NO: 66, a B09 polypeptide having the amino acid sequence SEQ ID NO: 49, and a B44 polypeptide having the aa sequence SEQ ID NO: 44.

12. The immunogenic composition as in any of claims 6-11, wherein each polypeptide is non-lipidated.

13. The immunogenic composition as in any of claims 6-11, wherein each polypeptide is non-pyruvylated.

14. An isolated nucleic acid sequence encoding an isolated non-lipidated and non-pyruvylated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 71.

15. The isolated nucleic acid sequence according to claim 14, wherein the nucleic acid sequence comprises SEQ ID NO: 72.

16. An immunogenic composition comprising an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B, and at least one conjugate selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135; and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y,

wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

17. The immunogenic composition according to claim 16, wherein the composition comprises at least two conjugates selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135; and

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y.

18. The immunogenic composition according to claim 16, wherein the composition comprises at least three conjugates selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135; and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y.

19. The immunogenic composition according to claim 16, wherein the composition comprises a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A; a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C; a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135; and a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y.

20. The immunogenic composition according to claim 16, wherein the polypeptide is a subfamily A polypeptide having any one of the amino acid sequences of SEQ ID NOs: 260 to 278 from WO2003063766.

21. The immunogenic composition according to claim 16, wherein the polypeptide is a subfamily B polypeptide having any one of the amino acid sequences of SEQ ID NOs: 279 to 299 from WO2003063766.

22. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated A05 having the amino acid sequence of SEQ ID NO: 55.

23. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated A12 having the amino acid sequence of SEQ ID NO: 66.

24. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated A22 having the amino acid sequence of SEQ ID NO: 68.

25. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B01 having the amino acid sequence of SEQ ID NO: 57.

26. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B03 having the amino acid sequence of SEQ ID NO: 17, wherein the cysteine at position 1 of SEQ ID NO: 17 is deleted.

27. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B09 having the amino acid sequence of SEQ ID NO: 49.

28. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B15 having the amino acid sequence of SEQ ID NO: 59, wherein the cysteine at position 1 of SEQ ID NO: 59 is deleted.

29. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B16 having the amino acid sequence of SEQ ID NO: 60, wherein the cysteine at position 1 of SEQ ID NO: 59 is deleted.

30. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B22, having the amino acid sequence of SEQ ID NO: 75.

31. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B24 having the amino acid sequence of SEQ ID NO: 80.

32. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated B44 having the amino acid sequence of SEQ ID NO: 44.

33. The immunogenic composition according to claim 16, wherein the polypeptide is a non-pyruvylated non-lipidated A62 having the amino acid sequence of SEQ ID NO: 71.

34. The immunogenic composition according to claim 16, wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 44, SEQ ID NO: 49, SEQ ID NO: 55, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 81, and SEQ ID NO: 75.

35. Use of an immunogenic composition comprising an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B, and at least one conjugate selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A,

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C,

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135, and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y

in the manufacture of a medicament for inducing an immune response against *Neisseria meningitidis* in a mammal, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

36. An immunogenic composition comprising an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B in the manufacture of a medicament for eliciting a bactericidal antibody against *Neisseria meningitidis* serogroup C in a mammal, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

37. The composition according to claim 36, wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 71 or the amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ

ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, wherein the cysteine at position 1 is deleted.

38. The composition according to claim 36, wherein the immunogenic composition further comprises at least one conjugate selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A,

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C,

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135, and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y.

39. An immunogenic composition comprising an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B in the manufacture of a medicament for eliciting a bactericidal antibody against *Neisseria meningitidis* serogroup Y in a mammal, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

40. The composition according to claim 39, wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 71 or the amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, wherein the cysteine at position 1 is deleted.

41. The composition according to claim 39, wherein the immunogenic composition further comprises at least one conjugate selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A,

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C,

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135, and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y.

42. Use of an immunogenic composition comprising an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B, and at least one conjugate selected from:

a) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup A,

b) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup C,

c) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup W135, and

d) a conjugate of a capsular saccharide of *Neisseria meningitidis* serogroup Y

in the manufacture of a medicament for eliciting a bactericidal antibody against *Neisseria meningitidis* in a mammal, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

43. An isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

44. The polypeptide according to claim 43, wherein the sequence comprises SEQ ID NO: 71.

45. The polypeptide according to claim 43, wherein the polypeptide is lipidated.

46. The polypeptide according to claim 43, wherein the polypeptide is non-lipidated.

47. The polypeptide according to claim 43, wherein the polypeptide is non-pyruvylated.

48. The polypeptide according to claim 43, wherein the polypeptide is non-lipidated and non-pyruvylated.

49. The polypeptide according to claim 43, wherein the polypeptide is immunogenic.

What is claimed is:

1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 70.

2. The polypeptide according to claim 1, wherein the sequence comprises SEQ ID NO: 71, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 70.

3. The polypeptide according to claim 1, wherein the polypeptide is immunogenic.

4. The polypeptide according to claim 1, wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry.

5. The isolated polypeptide according to claim 1, wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.

6. The isolated polypeptide according to claim 1, wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 71.

7. An immunogenic composition comprising the polypeptide as in any of claims 1 2-5, and 6.

8. The immunogenic composition according to claim 1, further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 49, wherein an N-terminal cysteine at position 1 is deleted as compared to SEQ ID NO: 18.